Sansure Biotech(SH:688289) Sou Hu Cai Jing·2025-06-26 11:52Group 1 - The core business of the company is to provide integrated in vitro diagnostic solutions centered on independent innovation in gene technology, including diagnostic reagents, instruments, and third-party medical testing services [2] - The company has significantly enhanced its brand recognition and industry position, receiving high recognition and honors from authoritative institutions both domestically and internationally [2] - The company has been listed in the global top 100 medical device companies for two consecutive years and has received various national and provincial certifications [2] Group 2 - As of March 31, 2025, the company had 20,629 shareholders, an increase of 205 from the previous period, with an average holding value of 352,800 yuan and an average holding of 27,600 shares per shareholder [1] - The company's latest quarterly report for Q1 2025 shows a revenue of 475 million yuan, a year-on-year increase of 21.62%, and a net profit of 91.73 million yuan, a year-on-year increase of 13.22%, with a gross profit margin of 76.71% [2] - The company's rolling price-to-earnings (PE) ratio is 41.00, compared to the industry average of 49.45 and the industry median of 35.92, ranking 85th in the medical device industry [1][3]